Preparation of enantiopure (R)-hydroxy metabolite of denbufylline using immobilized Lactobacillus kefiri DSM 20587 as a catalyst.

Lactobacillus kefiri DSM 20587 cells were immobilized in calcium alginate and carrageenan. The immobilized cells were used as biocatalysts for the enantioselective reduction of the methyl ketone group of denbufylline to synthesize the enantiopure (R)-hydroxy metabolite: (-)-1,3-dibutyl-7-((2'R)-hydroxypropyl)-1H-purine-2,6(3H,7H)-dione (1). The experimental conditions for the biotransformation were optimized. As denbufylline is insoluble in aqueous media, the influence of cosolvents (dimethylsulfoxide (DMSO), acetonitrile) and different concentrations of each solvent in the reaction mixture on the yield and enantiomeric excess of the final biotransformation product was studied. The maximum biotransformation yield (96-98%) and highest enantioselectivity (96% ee) for the obtained metabolite were reached using DMSO as a cosolvent at a concentration of 7.5% (v/v) in the presence of L. kefiri immobilized either in calcium alginate or in carrageenan. The absolute configuration of the stereogenic center of 1 was determined by applying Mosher's method.

[1]  D. Żelaszczyk,et al.  Enantioselective reduction of pentoxifylline to lisofylline using whole‐cell Lactobacillus kefiri biotransformation , 2007, Biotechnology journal.

[2]  S. Dallavalle,et al.  Absolute configuration of sporotricale and structure of 6-hydroxysporotricale. , 2006, Journal of natural products.

[3]  C. Wandrey,et al.  Synthesis of enantiopure (5R)-hydroxyhexane-2-one with immobilised whole cells of Lactobacillus kefiri , 2006, Applied Microbiology and Biotechnology.

[4]  C. Müller,et al.  Synthesis of xanthine derivatives by microwave-assisted ring closure reaction , 2005 .

[5]  J. Sinisterra,et al.  Enantioselective production of halohydrin precursor of Propranolol catalysed by immobilized yeasts , 2005 .

[6]  D. Weuster‐Botz,et al.  Asymmetric synthesis of the chiral synthon ethyl (S)-4-chloro-3-hydroxybutanoate using Lactobacillus kefir , 2005 .

[7]  D. Weuster‐Botz,et al.  Asymmetric synthesis of tert-butyl (3R, 5S) 6-chloro-dihydroxyhexanoate with Lactobacillus kefir , 2005, Applied Microbiology and Biotechnology.

[8]  D. Weuster‐Botz,et al.  Production of Lactobacillus kefir cells for asymmetric synthesis of a 3,5-dihydroxycarboxylate , 2005, Applied Microbiology and Biotechnology.

[9]  H. Sahm,et al.  Enantioselective reduction of carbonyl compounds by whole-cell biotransformation, combining a formate dehydrogenase and a (R)-specific alcohol dehydrogenase , 2005, Applied Microbiology and Biotechnology.

[10]  T. Wenzel,et al.  Chiral reagents for the determination of enantiomeric excess and absolute configuration using NMR spectroscopy. , 2003, Chirality.

[11]  A. Liese,et al.  Diastereoselective synthesis of optically active (2R,5R)-hexanediol , 2002, Applied Microbiology and Biotechnology.

[12]  Udo Kragl,et al.  Dehydrogenases in the Synthesis of Chiral Compounds , 2000 .

[13]  A. Korczyn,et al.  Denbufylline in Dementia: A Double-Blind Controlled Study , 1999, Dementia and Geriatric Cognitive Disorders.

[14]  K. Ohya,et al.  Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. , 1997, Biochemical pharmacology.

[15]  J. Sinisterra,et al.  Influence of the Immobilization Methodology in the Stability and Activity of P. putida UV4 Immobilized Whole Cells , 1996 .

[16]  U. Prüße,et al.  Stable support materials for the immobilization of viable cells , 1996 .

[17]  M. Ashton,et al.  Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. , 1994, Journal of medicinal chemistry.

[18]  J. Karlsson,et al.  Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. , 1993, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[19]  R. Hust,et al.  Pharmacokinetics of denbufylline in healthy elderly subjects. , 1991, European journal of drug metabolism and pharmacokinetics.

[20]  A. Thawley,et al.  Specific high-performance liquid chromatography method for the quantitative determination of denbufylline and its metabolites in plasma , 1990 .

[21]  R. Matsuno,et al.  Baker’s Yeast Mediated Bioreduction. A New Procedure Using Ethanol as an Energy Source , 1989 .

[22]  S. Jackman,et al.  The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re‐uptake site , 1989, British journal of pharmacology.

[23]  Kaoru Nakamura,et al.  Stereochemical Control in Microbial Reduction. Part 6. Stereochemical Control on Yeast Reduction of α-Keto Esters. Reduction by Immobilized Baker′s Yeast in Hexane. , 1988 .

[24]  Kaoru Nakamura,et al.  Stereochemical control on yeast reduction of .alpha.-keto esters. Reduction by immobilized bakers' yeast in hexane , 1988 .

[25]  D. Angersbach,et al.  The effect of 7-(2'-oxopropyl)-1,3-di-n-butyl-xanthine (BRL 30892) on ischaemic skeletal muscle pO2, pH and contractility in cats and rats. , 1984, Arzneimittel-Forschung.

[26]  A. Burger,et al.  Analogs of Nucleotides. I. Theophyllinylalkylphosphonic Acids and Related Compounds1 , 1955 .